{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:26:19Z","timestamp":1780356379601,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die generalisierte pustul\u00f6se Psoriasis (GPP) ist eine inflammatorische Erkrankung, die prinzipiell lebensbedrohlich verlaufen kann. Im Gegensatz zur \u201eklassischen\u201c Psoriasis (Psoriasis vulgaris) geht diese mit einer sterilen Pustelbildung auf erythemat\u00f6ser Haut einher. Bislang gab es in Europa keine suffiziente, zugelassene Therapieoption, sodass die f\u00fcr die Psoriasis vulgaris eingesetzten Medikamente auch bei der GPP Verwendung fanden. Neuere Studien belegen, dass bei der GPP oft eine Mutation des Interleukin-36-Rezeptor-Antagonisten (IL-36Ra) zu einer gesteigerten Inflammation und entsprechend zur Krankheitsaktivit\u00e4t f\u00fchrt. Wir berichten den Fall einer schweren GPP mit einer kompletten Remission nach 2\u2011maliger Gabe von Spesolimab, einem neuen Interleukin-36-Rezeptor-Antik\u00f6rper.<\/jats:p>","DOI":"10.1007\/s00105-023-05140-7","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:59:37Z","timestamp":1679885977000},"page":"356-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Remission einer therapierefrakt\u00e4ren generalisierten pustul\u00f6sen Psoriasis unter dem Interleukin-36-Rezeptor-Inhibitor Spesolimab","Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab"],"prefix":"10.1007","volume":"74","author":[{"given":"Valentina Laura","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"issue":"3","key":"5140_CR1","doi-asserted-by":"publisher","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","volume":"11","author":"SE Choon","year":"2021","unstructured":"Choon\u00a0SE, Lebwohl\u00a0MG, Marrakchi\u00a0S et al (2021) Study protocol of the global effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open 11(3):e43666. https:\/\/doi.org\/10.1136\/bmjopen-2020-043666","journal-title":"BMJ Open"},{"issue":"11","key":"5140_CR2","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini\u00a0AA, Burden\u00a0AD, Capon\u00a0F et\u00a0al (2017) European consensus statement on phenotypes of pustular psoriasis. J\u00a0Eur Acad Dermatol Venereol 31(11):1792\u20131799. https:\/\/doi.org\/10.1111\/jdv.14386","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"5140_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham\u00a0MJ, Van Voorhees\u00a0AS, Lebwohl\u00a0MG (2019) An update on generalized pustular psoriasis. Expert Rev Clin Immunol 15(9):907\u2013919. https:\/\/doi.org\/10.1080\/1744666X.2019.1648209","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"5140_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala\u00a0S, Golembesky\u00a0AK, Bohn\u00a0RL, Esser\u00a0D (2020) The clinical, humanistic, and economic burden of generalized pustular psoriasis: a\u00a0structured review. Expert Rev Clin Immunol 16(3):239\u2013252. https:\/\/doi.org\/10.1080\/1744666X.2019.1708193","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"5140_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi\u00a0S, Guigue\u00a0P, Renshaw\u00a0BR et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N\u00a0Engl J Med 365(7):620\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1013068","journal-title":"N Engl J Med"},{"key":"5140_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3389\/fimmu.2019.01162","volume":"10","author":"AL Buhl","year":"2019","unstructured":"Buhl\u00a0AL, Wenzel\u00a0J (2019) Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol 10:1162. https:\/\/doi.org\/10.3389\/fimmu.2019.01162","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"5140_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger\u00a0J, Puig\u00a0L, Tha\u00e7i\u00a0D (2022) Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol 23(Suppl 1):51\u201364. https:\/\/doi.org\/10.1007\/s40257-021-00658-9","journal-title":"Am J Clin Dermatol"},{"issue":"26","key":"5140_CR8","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez\u00a0H, Choon\u00a0SE, Marrakchi\u00a0S et\u00a0al (2021) Trial of spesolimab for generalized pustular psoriasis. N\u00a0Engl J Med 385(26):2431\u20132440. https:\/\/doi.org\/10.1056\/NEJMoa2111563","journal-title":"N Engl J Med"},{"issue":"10","key":"5140_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez\u00a0H, Choon\u00a0SE, Marrakchi\u00a0S et al (2019) Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N\u00a0Engl J Med 380(10):981\u2013983. https:\/\/doi.org\/10.1056\/NEJMc1811317","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"5140_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi\u00a0S, Puig\u00a0L (2022) Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol 23(Suppl 1):13\u201319. https:\/\/doi.org\/10.1007\/s40257-021-00655-y","journal-title":"Am J Clin Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:23:39Z","timestamp":1683768219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05140-7","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"10 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.L.\u00a0M\u00fcller und A.\u00a0Kreuter geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}